The number of people dying in poverty has increased by 19% in the past four years, according to a new report created by ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CRSP stock, giving a Buy rating on November 6. Salim Syed’s rating is based on a combination of encouraging developments ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term ...

After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average, suggesting a ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...

Here are seven of the best Vanguard index funds to buy today: ...

With the election just one week away, Tim Chubb, Girard CIO, joins Market Domination to discuss how investors can best navigate the market ahead. Girard recommends "shifting into neutral" as the ...